User login


Former USTR official: USMCA does not prevent changes to U.S. biologics law

August 27, 2019 at 1:44 PM
Ratifying the U.S.-Mexico-Canada Agreement would not impede Congress from reducing the exclusivity period for biologics, according to a former Obama administration trade official. Miriam Sapiro, a former acting and deputy U.S. Trade Representative in the Obama administration, in a memo for the Pass USMCA Coalition, said the U.S. could amend USMCA if it reduced the exclusivity biologics period. Some House Democrats have demanded USTR renegotiate USMCA’s requirement for an exclusivity period for biologics of at least 10 years, arguing that...

Not a subscriber? Sign up for 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Trump administration.